CUE — Cue Biopharma

Founder-Led

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

Trend Edge Setup Score

Trend Edge rates CUE Bullish with a Setup Score of 36, net conviction 21, actionability 62. How the Setup Score works →

Total Setup Score36
Directional BiasBullish
Net Conviction21
Actionability62 (in range)

Key signals behind this score

About Cue Biopharma

Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation. Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$27.67
Market Cap$205M
Float6.8M
Shares Outstanding7.3M
Price/Sales (TTM)5.43
vs. Analyst Target+315.6% to analyst PT
Operating Margin (TTM)-1113.31%
Revenue (TTM)$37.7M
Dividend RateNone
Analyst Target Price$115.00 (4 analysts)

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2020 $3.2M -$44.8M -$30.4M -$44.0M
2021 $14.9M -$44.2M $14.9M -$45.5M
2022 $1.2M -$53.0M $1.2M -$50.5M
2023 $5.5M -$50.7M -$32.6M -$46.1M
2024 $9.3M -$40.7M $9.3M -$37.5M
2025 $27.5M -$26.6M $27.5M -$22.3M

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Sep 2025 $2.1M -$7.4M
Dec 2025 $21.9M $1.6M
Mar 2026 $5.7M -$5.2M
Jun 2026 $7.9M -$153M

Ownership & Float

Insider Ownership7.2%
Institutional Ownership22.6%
Short Float5.1%
% of All Funds Holding0.56%
Number of Funds Holding49

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$29.60Near-term / short-term trend
Weekly40-Week SMA$19.02Medium-term trend
Weekly80-Week SMA$21.13Cyclical trend (business cycle)
Weekly200-Week SMA$50.20Secular trend (multi-year)
Monthly10-Month SMA$18.27Near-term monthly trend
Monthly20-Month SMA$20.93Medium-term monthly trend
Monthly40-Month SMA$39.55Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$5.80 support 8.02x 4 months ago
$49.00 resistance 1.30x 21 months ago

Historical Earnings Reactions (35 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap -0.45% 0.00% 48.57% 4.49% -8.92%
1 Day -1.70% -0.70% 42.86% 19.74% -20.37%
1 Week -4.89% -2.45% 34.29% 31.45% -32.22%
2 Weeks -5.97% -6.39% 34.29% 18.77% -27.67%
1 Month -2.13% -7.37% 36.36% 94.23% -38.62%

Next earnings: November 2, 2026 (59 days away)

Seasonality & Day-of-Week Patterns

Monthly Seasonality

MonthAvg ReturnWin RateSamples
Jan5.1%62.5%8
Feb-5.7%33.3%9
Mar-6.3%22.2%9
Apr18.6%55.6%9
May5.4%44.4%9
Jun-5.1%33.3%9
Jul-9.8%33.3%9
Aug-2.3%44.4%9
Sep-5.0%37.5%8
Oct7.5%50.0%8
Nov7.5%62.5%8
Dec-8.3%37.5%8

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday 0.26% 48.7% 409
Tuesday -0.23% 43.5% 448
Wednesday 0.40% 49.7% 445
Thursday -0.28% 42.7% 438
Friday 0.24% 44.5% 436

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 22.6%

Insider Transactions — Smart Summary

Total insider ownership: 7.2%

Founder-led management: Ronald Seidel (Co-Founder)

12-Month Insider Activity Summary

Total Filings4
Net Value-$2.0M
Net Shares Change392,164
% of Float5.7%
C-Suite Filings3
Clusters Detected1

Key Insiders

NameTitleNet ValueFilingsActivity
Lin Shao-Lee Chief Executive Officer -$1.6M 1 N/A
Ray Sumita Chief Legal Compliance Officer -$265,627.528 1 N/A
Meluzio Michael Vincent VP, Prin. Accounting Officer -$169,323.445 1 N/A
Sarraf Pasha +$99,747.956 1 1 buy

Transaction Clusters

PeriodFilingsInsidersNet ValueSeniority
2026-08-14 – 2026-08-17 3 3 -$2.0M 3 C-suite

Significant Filings

DateInsiderTitleNet ValuePrice After
2026-01-02 Sarraf Pasha +$99,747.956 Transaction at $0.31, now +8883.8%
2026-08-17 Meluzio Michael Vincent VP, Prin. Accounting Officer -$169,323.445 Transaction at $30.09, now -8.0%
2026-08-14 Lin Shao-Lee Chief Executive Officer -$1.6M Transaction at $27.58, now +0.3%
2026-08-17 Ray Sumita Chief Legal Compliance Officer -$265,627.528 Transaction at $30.09, now -8.0%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Cue Biopharma (CUE) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for CUE on Trend Edge →